SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH L impact

VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Click For Rel

VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

VTGN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.